natgillin/translations-raw huggingface dataset:
Regadenoson may have a modest inhibitory effect on the active renal transporter, OCT2, and has been found to be likely substrate for BCRP, ENT1 or ENT2 mediated transport.
Regadenozon ima morda zmerno inhibitorno delovanje na aktivni renalni prenašalec, OCT2, ugotovili so tudi, da je verjeten substrat za transport, pri katerem posredujejo BCRP, ENT1 ali ENT2.
Patients from both groups (exercise with regadenoson and regadenoson only) underwent a SPECT Myocardial Perfusion Imaging (MPI) at 60-90 minutes post-regadenoson administration.
Bolniki iz obeh skupin (vadba z regadenozonom in samo regadenozon) so opravili slikanje miokardne perfuzije SPECT (MPI- Myocardial Perfusion Imaging) v času 60-90 minut po uporabi regadenozona.
(n = 1,113)
ADVANCE MPI 1 (n = 1.113)
It is unknown whether regadenoson is excreted in human breast milk.
Ni znano, ali se regadenozon izloča v materino mleko.
It is injected directly into a vein, as a single dose of 400 micrograms in a 5 ml solution - the injection will take about 10 seconds to complete.
Zdravilo se injicira neposredno v veno v obliki enkratnega odmerka 400 mikrogramov v 5-ml raztopini - injiciranje traja približno 10 sekund.
Like all medicines, Rapiscan can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi to zdravilo neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
Signs of maternal and fetal toxicity were seen in rats and rabbits (reduced fetal weights, delays in ossification [rats], reduced litter size and number of live fetuses [rabbits]), but not teratogenicity.
Pri podganah in kuncih so videli znake toksičnosti za brejo samico in plod (zmanjšana telesna masa fetusa, zakasnjena osifikacija [podgane], manjše število legla in število živih fetusov [kunci]), vendar niso opazili teratogenosti.
Intravenous use.
Intravenska uporaba.
Activation of the A2A adenosine receptor produces coronary vasodilation and increases coronary blood flow (CBF).
Aktiviranje receptorja adenozina A2A povzroči koronarno vazodilatacijo in zviša koronarni krvni pretok.
Regadenoson has the potential to cause serious and life-threatening reactions, including those listed below (see also section 4.8).
Regadenozon lahko povzroči resne ali življenjsko nevarne učinke, vključno s spodaj naštetimi (glejte tudi poglavje 4.8).
Use of regadenoson involving exercise has been associated with serious adverse reactions including hypotension, hypertension, syncope and cardiac arrest.
Uporaba regadenozona v kombinaciji s telesno vadbo je bila povezana z resnimi neželenimi učinki, vključno s hipotenzijo, hipertenzijo, sinkopo in srčnim zastojem.
• Unstable angina that has not been stabilised with medical therapy.
• nestabilna angina pektoris, ki ni uravnana z zdravili,
Regadenoson may cause myocardial ischaemia (potentially associated with fatal cardiac arrest, lifethreatening ventricular arrhythmias, and myocardial infarction), hypotension leading to syncope and transient ischaemic attacks, elevated blood pressure leading to hypertension and hypertensive crises, and SA/AV node block leading to first, second or third degree AV block, or sinus bradycardia requiring intervention (see section 4.4).
Regadenozon lahko povzroči miokardno ishemijo (potencialno povezano s srčnim zastojem s smrtnim izidom, življenje ogrožajoče ventrikularne aritmije in miokardni infarkt), hipotenzijo, ki povzroči sinkopo in tranzitorne ishemične atake, povišan krvni tlak, ki povzroči hipertenzijo in hipertenzivne krize, ter blok SA/AV vozlov, ki povzroči AV blok prve, druge ali tretje stopnje ali sinusno bradikardijo, zaradi katere je potrebno posredovanje (glejte poglavje 4.4).
The recommended dose is a single injection of 400 micrograms regadenoson (5 ml) into a peripheral vein, with no dose adjustment necessary for body weight.
Priporočeni odmerek je 400 mikrogramov regadenozona (5 ml) v enkratnem odmerku injiciran v periferno veno, pri čemer prilagajanje odmerka na telesno maso ni potrebno.
You will also be given an injection of sodium chloride 9 mg/ml (0.9%) solution (5 ml), and an injection of a small amount of a radioactive substance (radiopharmaceutical).
Dobili boste tudi injekcijo 0,9% (9 mg/ml) raztopine natrijevega klorida (5 ml) in injekcijo majhne količine radioaktivne snovi (radiofarmacevtskega izdelka).
Adenosine was administered first, followed by regadenoson as its hyperaemia may last unpredictably and the measured FFR values were compared.
Najprej so aplicirali adenozin, nato regadenozon, saj je trajanje z njim povzročene hiperemije lahko nepredvidljivo, izmerjene vrednosti FFR pa so primerjali.
Aminophylline (100 mg, administered by slow intravenous injection over 60 seconds) injected 1 minute after 400 micrograms regadenoson in subjects undergoing cardiac catheterisation, was shown to shorten the duration of the coronary blood flow response to regadenoson as measured by pulsed- wave Doppler ultrasonography.
Aminofilin (100 mg, ki ga dajemo s počasnim intravenskim injiciranjem v 60 sekundah), injiciran 1 minuto po uporabi 400 mikrogramov regadenozona pri osebah mad kateterizacijo srca, je pokazal, da skrajša trajanje odziva koronarnega krvnega pretoka na regadenozon, izmerjeno s pulznim doplerjem.
• if you have slow heart rate (high degree heart block or sinus node disease), and don't have a pacemaker fitted.
• če imate počasen utrip srca (srčni blok visoke stopnje ali bolezen sinusnega vozla) in nimate nameščenega srčnega spodbujevalnika,
• redness of the skin
• pordelost kože
An increase in blood pressure has been observed in some patients (maximum systolic blood pressure of 240 mm Hg and maximum diastolic blood pressure of 138 mm Hg).
Pri nekaterih bolnikih so opazili zvišanje krvnega tlaka (največji sistolični krvni tlak 240 mm Hg in največji diastolični krvni tlak 138 mm Hg).
The risk of serious hypotension may be higher in patients with autonomic dysfunction, hypovolemia, left main coronary artery stenosis, stenotic valvular heart disease, pericarditis or pericardial effusions, or stenotic carotid artery disease with cerebrovascular insufficiency.
Tveganje hude hipotenzije je lahko večje pri bolnikih z avtonomno disfunkcijo, hipovolemijo, stenozo v glavnem deblu leve koronarne arterije, stenotično boleznijo srčne zaklopke, perikarditisom ali perikardno efuzijo ali stenotično boleznijo karotidne arterije s cerebrovaskularno insuficienco.
In the first and second studies, dyspnoea was reported as an adverse reaction following regadenoson dosing (61% for patients with COPD; 34% for patients with asthma) while no subjects experienced dyspnoea following placebo dosing.
V prvi in drugi študiji so poročali o dispneji kot o neželenem učinku po dajanju regadenozona (61% za bolnike s KOPB; 34% za bolnike z astmo), pri bolnikih, ki so prejeli placebo, pa ni bilo primerov dispneje.
To be taken into consideration by patients on a controlled sodium diet.
To morajo upoštevati bolniki, ki so na dieti z nadzorovanim vnosom natrija.
Fertility and pre- and post-natal studies have not been conducted.
Študij vpliva na razmnoževanje ter prenatalnih in postnatalnih študij niso izvajali.
In the second study in 48 patients with mild to moderate asthma who had previously been shown to have bronchoconstrictive reactions to adenosine monophosphate, the rate of FEV1 reduction > 15% from baseline was the same (4%) following both regadenoson and placebo dosing.
V drugi študiji z 48 bolniki z blago do zmerno astmo, pri katerih se je že prej pokazala bronhokonstrikcijska reakcija na adenozin monofosfat, je bila stopnja zmanjšanja FEV1 > 15% od izhodišča enaka (4%) po dajanju regadenozona in placeba.
Continuous ECG monitoring should be performed and vital signs should be monitored at frequent intervals until the ECG parameters, heart rate and blood pressure have returned to pre-dose levels.
Potreben je stalen nadzor EKG in preverjanje življenjskih znakov v pogostih časovnih presledkih, dokler se parametri EKG, srčnega utripa in krvnega tlaka ne vrnejo na vrednosti pred odmerjanjem.
Do not take Rapiscan:
Ne jemljite zdravila Rapiscan
Vomiting, nausea, oral discomfort
Pogosti bruhanje, navzea, ustno nelagodje
• discomfort in the stomach
• nelagodje v trebuhu
The most common cardiovascular histories included hypertension (81%), coronary artery bypass graft (CABG), percutaneous transluminal coronary angioplasty (PTCA) or stenting (51%), angina (63%), and history of myocardial infarction (41%) or arrhythmia (33%); other medical history included diabetes (32%) and COPD (5%).
Najpogostejše kardiovaskularne anamneze so vključevale hipertenzijo (81%), obvodni presadek koronarne arterije (CABG- coronary artery bypass graft), perkutano transluminalno koronarno angioplastiko (percutaneous transluminal coronary angioplasty, PTCA) ali stentiranje (51%), angino pektoris (63%) in anamnezo miokardnega infarkta (41%) ali aritmije (33%); druge anamneze so vključevale diabetes (32%) in KOPB (5%).
For use in FFR: This product is to be administered no more than twice, no less than10 minutes apart, during any 24 hour period.
Pri uporabi za FFR: To zdravilo se sme uporabiti največ dvakrat, z vsaj 10-minutnim razmakom v 24urnem obdobju.
Rapiscan is also used during catheterisation and imaging arteries of the heart (invasive coronary angiography) to expand the arteries of the heart to measure the difference in pressure, caused by a narrowing within one or more arteries.
Zdravilo Rapiscan se uporablja tudi med kateterizacijo in slikanjem arterij v srcu (invazivna koronarna angiografija) za razširitev srčnih arterij in merjenje razlike v tlaku, do katere pride zaradi zoženja ene ali več arterij.
What Rapiscan looks like and contents of the pack
Izgled zdravila Rapiscan in vsebina pakiranja
Adenosine receptor agonists including regadenoson induce arterial vasodilation and hypotension.
Agonisti receptorjev adenozina vključno z regadenozonom inducirajo arterijsko vazodilatacijo in hipotenzijo.
Sinoatrial and atrioventricular nodal block
Blok sinoatrijskega in atrioventrikularnega vozla
With increasing renal impairment, from mild (CLcr 50 to < 80 ml/min) to moderate (CLcr 30 to < 50 ml/min) to severe renal impairment (CLcr < 30 ml/min), the fraction of regadenoson excreted unchanged in urine and the renal clearance decreased, resulting in increased elimination halflives and AUC values compared to healthy subjects (CLcr ml/min).
Z večanjem okvare ledvic, od blage (očistek kreatinina 50 to < 80 ml/min) do zmerne (očistek kreatinina 30 do < 50 ml/min) in hude okvare ledvic (očistek kreatinina < 30 ml/min), se je frakcija regadenozona nespremenjena izločala v urinu in ledvični očistek se je manjšal, kar je povzročilo podaljšanje razpolovnih časov izločanja in vrednosti AUC v primerjavi z zdravimi osebami (očistek kreatinina ≥ 80 ml/min).
• an allergic reaction which can cause rash, wheals/weals, swelling under the skin near the eyes or throat, throat tightness, difficulty breathing
• alergijska reakcija, ki lahko povzroči izpuščaje, izbočene lise, podkožno oteklino blizu oči ali grla, stiskanje v grlu in težave z dihanjem
5 ml solution in a single use Type 1 glass vial with (butyl) rubber stopper and aluminium over-seal.
5 ml raztopine v stekleni viali (tipa 1) za enkratno uporabo z (butilnim) gumijastim zamaškom in aluminijasto vrhnjo zaporko.
This medicinal product should be inspected visually for particulate matter and discolouration prior to administration.
To zdravilo je treba pred uporabo vizualno pregledati glede delcev in obarvanja.
In ADVANCE MPI 1 and ADVANCE MPI 2, the following pre-specified safety and tolerability endpoints comparing regadenoson to adenosine achieved statistical significance: (1) a summed score of both the presence and severity of the symptom groups of flushing, chest pain, and dyspnoea was lower with regadenoson (0.9 ± 0.03) than with adenosine (1.3 ± 0.05); and (2) the symptom groups of flushing (21% vs 32%), chest pain (28% vs 40%), and ‘throat, neck or jaw pain' (7% vs 13%) were less frequent with regadenoson ; the incidence of headache (25% vs 16%) was more frequent with regadenoson .
V študijah ADVANCE MPI 1 in ADVANCE MPI 2 je bila v naslednjih predhodno specificiranih končnih točkah varnosti in prenašanja, pri katerih so primerjali regadenozon z adenozinom, dosežena statistično značilna razlika: (1) seštevek vsot prisotnosti in resnosti skupin simptomov vročinskih valov, bolečine v prsih in dispneje je bil nižji z regadenozonom (0,9 ± 0,03) kot z adenozinom (1,3 ± 0,05); in (2) skupina simptomov vročinskih valov (21% v primerjavi z 32%), bolečine v prsih (28% v primerjavi s 40%) in bolečine grla, vratu ali čeljusti (7% v primerjavi s 13%) pa je bila manj pogosta z regadenozonom; pojavnost glavobola (25% v primerjavi s 16%) je bila bolj pogosta z regadenozonom.
Myocardial radiopharmaceutical uptake after regadenoson administration is therefore greater in areas perfused by normal relative to stenosed arteries.
Miokardni privzem radiofarmacevtskega izdelka po dajanju regadenozona je zato večji v predelih, ki jih oskrbujejo normalne arterije kot v tistih, ki jih oskrbujejo stenotične.
Patients with a recent history of serious uncontrolled ventricular arrhythmia, myocardial infarction, or unstable angina, a history of greater than first degree AV block, or with symptomatic bradycardia, sick sinus syndrome, or a heart transplant were excluded.
Bolniki z anamnezo nedavne hude nenadzirane ventrikularne aritmije, miokardnim infarktom ali nestabilno angino pektoris, z anamnezo AV bloka več kot prve stopnje ali s simptomatsko bradikardijo, sindromom bolnega sinusa ali srčnim presadkom so bili izključeni.
No dose adjustment is needed in elderly patients.
Pri starejših bolnikih ni treba prilagajati odmerka.
Hyperaemia may fluctuate between sub-maximum and maximum until it slowly vanishes.
Izraženost hiperemije lahko niha med vrednostjo, ki je manjša od največje, in največjo vrednostjo, nato pa počasi izzveni.
• being sick (vomiting), feeling sick (nausea)
• slabost (bruhanje), občutek slabosti (navzea)
Regadenoson preferentially increases blood flow in coronary relative to peripheral (forelimb, brain, pulmonary) arterial vascular beds in the anaesthetised dog.
Regadenozon preferenčno zvišuje pretok krvi v koronarnih arterijah glede na periferne arterijske žilne sisteme (prednjih tac, možgan, pljuč) anesteziranih psov.
In post-marketing experience there have also been reports of cerebrovascular accident (CVA).
V obdobju trženja so poročali tudi o cerebrovaskularnem inzultu.
Rarely, Rapiscan can cause a stroke (also known as a cerebrovascular accident).
V redkih primerih lahko zdravilo Rapiscan povzroči možgansko kap (t. i. cerebrovaskularni inzult);
After the initial scan, patients were randomised to either regadenoson or adenosine, and received a second stress scan with the same radionuclide imaging protocol as that used for the initial scan.
Po začetnem slikanju so bili bolniki naključno razvrščeni v bodisi skupino, ki je prejela regadenozon ali adenozin, nato pa so bili še drugič slikani pod obremenitvijo z enakim protokolom radionuklidnega slikanja kot je bil uporabljen za prvo slikanje.
• if you have heart failure.
• če imate srčno popuščanje,
Do not eat food or have drinks containing caffeine (for example, tea, coffee, cocoa, cola or chocolate) for at least 12 hours before you are given Rapiscan.
Vsaj 12 ur, preden prejmete zdravilo Rapiscan, ne uživajte hrane ali pijače, ki vsebuje kofein (na primer čaj, kava, kakav, kola ali čokolada).
The most common adverse reactions reported during clinical development in a total of 1,651 patients/subjects were: dyspnoea (29%), headache (27%), flushing (23%), chest pain (19%), electrocardiogram ST segment changes (18%), gastrointestinal discomfort (15%) and dizziness (11%).
Najpogostejši neželeni učinki, o katerih so poročali med kliničnim razvojem pri skupaj 1.651 bolnikih/prostovoljcih, so bili: dispneja (29%), glavobol (27%), vročinski vali (23%), bolečina v prsih (19%), spremembe segmentov ST v elektrokardiogramu (18%), prebavno nelagodje (15%) in omotica (11%).
In patients undergoing coronary catheterisation, pulsed-wave Doppler ultrasonography was used to measure the average peak velocity (APV) of CBF before and up to 30 minutes after administration of regadenoson (400 micrograms, intravenously).
Pri bolnikih, pri katerih se opravi koronarna kateterizacija, so uporabili Dopplerjev pulzni ultrazvok za merjenje povprečne hitrosti vrha koronarnega krvnega pretoka pred dajanjem regadenozona in še do 30 minut po tem (400 mikrogramov, intravensko).
Systolic blood pressure and diastolic blood pressure changes were variable, with the greatest mean change in systolic pressure of −3 mm Hg and in diastolic pressure of −4 mm Hg approximately 1 minute after regadenoson administration.
Spremembe sistoličnega krvnega tlaka in diastoličnega krvnega tlaka sta se spreminjali, pri čemer je bila največja srednja sprememba sistoličnega tlaka −3 mm Hg in diastoličnega tlaka −4 mm Hg približno 1 minuto po dajanju regadenozona.
The baseline MPI scan at rest, and the MPI scans for the exercise with regadenoson and regadenoson only groups constituted the MPI 1 phase.
Izhodiščno slikanje MPI v mirovanju in slikanja MPI za vadbo z regadenozonom ter samo samo regadenozon predstavljajo fazo MPI 1.
Cardiac resuscitation equipment and trained staff should be available before administering regadenoson (see section 4.4).
Pred dajanjem regadenozona mora biti prisotno usposobljeno osebje, ki ima na voljo opremo za oživljanje srca (glejte poglavje 4.4).
Treatment with Rapiscan is restricted to use in a medical facility where cardiac monitoring and resuscitation equipment are available.
Zdravljenje z zdravilom Rapiscan je omejeno na uporabo v zdravstveni ustanovi, kjer obstaja možnost nadziranja srčne funkcije in je na voljo oprema za oživljanje srca.
Regadenoson should be used with caution in patients with a history of atrial fibrillation or flutter.
Regadenozon je treba previdno uporabljati pri bolnikih z atrijsko fibrilacijo ali undulacijo v anamnezi.
In clinical trials, increased systolic blood pressure (≥ 50 mm Hg) was observed in 0.7% of patients and increased diastolic blood pressure (≥ 30 mm Hg) in 0.5% of patients.
V kliničnih preskušanjih so opazili povišan sistolični krvni tlak (≥ 50 mmHg) pri 0,7 % bolnikov in povišan diastolični krvni tlak (≥ 30 mmHg) pri 0,5 % bolnikov.
Adenosine receptor agonists including regadenoson can depress the sinoatrial (SA) and AV nodes and may cause first, second or third degree AV block, or sinus bradycardia.
Agonisti receptorjev adenozina vključno z regadenozonom lahko zatrejo sinoatrijske (SA) in AV vozle in povzročijo AV blok prve, druge ali tretje stopnje ali sinusno bradikardijo.
• sudden stopping of the heart or damage to the heart, heart block (a disorder of the heart's electrical signal, where the signal cannot pass from the upper to the lower chambers), slow heart beat
• nenadna ustavitev srca ali poškodovanje srca, srčni blok (motnja električnih signalov srca, ko signal ne more prehajati iz zgornjega v spodnji prekat), počasen srčni utrip
• dipyridamole, a medicine used to prevent blood clots, must not be used for at least two days before you are given Rapiscan because it can change the effect of Rapiscan.
• dipiridamola, zdravila za preprečevanje strjevanja krvi, ne smete uporabljati vsaj dva dni,
Ask your doctor for advice before using any medicine.
Posvetujte se z zdravnikom, preden vzamete to zdravilo.
Fertility Fertility studies with regadenoson have not been performed (see section 5.3).
Plodnost Študij vpliva na plodnost z regadenozonom niso izvedli (glejte poglavje 5.3).
Rapiscan is supplied in a carton containing a single use 5 ml glass vial with a rubber stopper and aluminium sealed cap.
Zdravilo Rapiscan je na voljo v škatli, ki vsebuje eno 5-mililitrsko stekleno vialo za enkratno uporabo z gumijastim zamaškom in aluminijasto zaporko.
The efficacy and safety of regadenoson for pharmacologic stress radionuclide MPI were determined relative to adenosine in two randomised, double- blind studies (ADVANCE MPI 1 and ADVANCE MPI 2) in 2,015 patients with known or suspected coronary artery disease who were referred for a clinically-indicated pharmacologic stress MPI.
Farmakološka obremenitev radionuklidnega slikanja miokardne perfuzije Učinkovitost in varnost regadenozona pri farmakološki obremenitvi radionuklidnega slikanja miokardne perfuzije so določali glede na adenozin v dveh randomiziranih, dvojno slepih študijah (ADVANCE MPI 1 in ADVANCE MPI 2) pri 2.015 bolnikih z znano boleznijo koronarne arterije ali s sumom nanjo, ki so bili napoteni na klinično indicirano radionuklidno slikanje miokardne perfuzije pod farmakološkim stresom.
If deemed necessary, a second dose of 400 micrograms can be injected at least 10 minutes after the first dose for such pressure difference measurement during the same catheterization procedure.
Če bi bilo potrebno, se za tako merjenje razlike v tlaku lahko drugi 400 mikrogramski odmerek injicira ne prej kot 10 minut po prvem odmerku v okviru istega kateterizacijskega postopka.
In the third study in 1009 patients with mild or moderate asthma (n=537) and moderate or severe COPD (n=472) the incidence of FEV1 reduction >15% from baseline was 1.1% and 2.9% in patients with asthma (p=0.15) and 4.2% and 5.4% in patients with COPD (p=0.58) following regadenoson and placebo dosing, respectively.
V tretji študiji pri 1009 bolnikih z blago do zmerno astmo (n=537) in zmerno do resno KOPB (n=472) je bila incidenca zmanjšanja FEV1 > 15% od izhodišča 1,1% in 2,9% pri bolnikih z astmo (p=0,15) in 4,2% in 5,4% pri bolnikih s KOPB (p=0,58) po dajanju regadenozona in placeba.
Rapiscan must not be used if the solution if it is discoloured or particulate matter is present.
Zdravilo Rapiscan se ne sme uporabiti, če je raztopina obarvana ali v njej plavajo delci.
During catheterisation of the arteries of the heart, your doctor may measure the pressure difference (also known as fractional flow reserve - FFR) due to a narrowing in one or more arteries of the heart.
Med kateterizacijo arterij v srcu lahko zdravnik izmeri razliko v tlaku (znano tudi kot funkcionalna pretočna rezerva - FFR) zaradi zožitve v eni ali več arterijah srca.
In the first study in 49 patients with moderate to severe COPD, the rate of FEV1 reduction > 15% from baseline was 12% and 6% following regadenoson and placebo dosing, respectively (p=0.31).
V prvi študiji pri 49 bolnikih z blago do resno KOPB je bila stopnja zmanjšanja FEV1 > 15% od izhodišča 12% po dajanju regadenozona in 6% po placebu (p = 0,31).
Caution should be used when administering regadenoson to patients with a history of seizures or other risk factors for seizures, including the concomitant administration of medicinal products that lower seizure threshold (e.g. antipsychotics, antidepressants, theophyllines, tramadol, systemic steroids and quinolones).
Pri dajanju regadenozona bolnikom z anamnezo epileptičnih napadov ali drugimi dejavniki tveganja za epileptične napade, vključno s sočasnim jemanjem zdravil, ki znižujejo prag za napade (npr. antipsihotiki, antidepresivi, teofilini, tramadol, sistemski steroidi in kinoloni), je potrebna previdnost.
• sudden stopping of the heart or damage to the heart, heart block (a disorder of the heart's electrical signal, where the signal cannot pass from the upper to the lower chambers), rapid heart beat
• nenadna ustavitev srca ali poškodovanje srca, srčni blok (motnja električnih signalov srca, ko signal ne more prehajati iz zgornjega v spodnji prekat), hiter srčni utrip;
Fetotoxicity, but not teratogenicity, was noted in embryo-fetal development studies (see section 5.3).
V študijah razvoja embria-zarodka so opazili fetotoksičnost, ne pa tudi teratogenosti (glejte poglavje 5.3).
Patients should remain sitting or lying down and be monitored at frequent intervals after the injection until the ECG parameters, heart rate and blood pressure have returned to pre-dose levels.
Bolniki naj ostanejo v sedečem ali ležečem položaju, in pod nadzorom v pogostih časovnih presledkih po injiciranju tako dolgo, dokler se parametri EKG, srčnega utripa in krvnega pritiska ne vrnejo na vrednosti pred odmerjanjem.